Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Justine V Cohen"'
Autor:
Andrew L Mammen, Jarushka Naidoo, Divyanshu Dubey, Michael Dougan, Teilo H Schaller, Meghan J Mooradian, Douglas B Johnson, Jorg Dietrich, Leyre Zubiri, Tomas G Neilan, Bianca D Santomasso, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Justine V Cohen, Nancy Wang, Jenny Linnoila, Jeffrey M Gelfand, Anthony A Amato, Stacey L Clardy, David A Reardon, William C Louv, Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Priscilla K Brastianos, Tracey A Cho, Christopher T Doughty, Jeffrey T Guptill, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Maria Martinez-Lage, Krista M Rubin, Karin Woodman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence
Externí odkaz:
https://doaj.org/article/a2206707f599451b8603379684ad2015
Autor:
Anju Nohria, Alexander R Lyon, Stephane Ederhy, Franck Thuny, Michael Mahmoudi, Magid Awadalla, Dahlia Banerji, Merna Armanious, Dipti Gupta, Sarju Ganatra, Paaladinesh Thavendiranathan, Gagan Sahni, Ryan Sullivan, Lili Zhang, Tomas G Neilan, Daniel A Zlotoff, Malek Z O Hassan, Amna Zafar, Raza M Alvi, Syed S Mahmood, Carol L Chen, Ana Barac, Maeve Jones-O'Connor, Sean P Murphy, Brian J Forrestal, Michael C Kirchberger, Otavio R Coelho-Filho, Muhammad A Rizvi, Anant Mandawat, Carlo G Tocchetti, Sarah Hartmann, Hannah K Gilman, Eduardo Zatarain-Nicolás, Lucie M Heinzerling, Justine V Cohen, John Groarke, Michael G Fradley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other
Externí odkaz:
https://doaj.org/article/e0d49c053cc347dfa4d4fbdd78de84e0
Autor:
Jeffrey C. Thompson, MD, MTR, Charu Aggarwal, MD, MPH, Janeline Wong, BS, Vivek Nimgaonkar, BS, Wei-Ting Hwang, PhD, Michelle Andronov, BS, David M. Dibardino, MD, Christoph T. Hutchinson, MD, MA, Kevin C. Ma, MD, Anthony Lanfranco, MD, MS, Edmund Moon, MD, Andrew R. Haas, MD, PhD, Aditi P. Singh, MD, Christine A. Ciunci, MD, MSCE, Melina Marmarelis, MD, MSCE, Christopher D’Avella, MD, Justine V. Cohen, DO, Joshua M. Bauml, MD, Roger B. Cohen, MD, Corey J. Langer, MD, Anil Vachani, MD, MSCE, Erica L. Carpenter, MBA, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100301- (2022)
Introduction: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed
Externí odkaz:
https://doaj.org/article/1e4a79ab12aa4b34955ec3972d774b0c
Autor:
Meghan J. Mooradian, James M. Cleary, Anita Giobbie‐Hurder, Lancia N. F. Darville, Aparna Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X. Chen, Susan Percy Ivy, Keiran S. M. Smalley, John M. Koomen, Ryan J. Sullivan
Publikováno v:
Cancer. 129:1904-1918
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-4 (2019)
Abstract Background Alongside its clinical success, checkpoint blockade has also given rise to a set of immune-related adverse events (irAEs). In addition to causing considerable morbidity and even mortality, irAEs may limit the success and scope of
Externí odkaz:
https://doaj.org/article/1ce80132625b43e7ac1832e946a17e1a
Autor:
Jessica Louise Smith, Alexander M. Menzies, Justine V. Cohen, Margarida Mut-Lloret, Alpaslan Ozgun, Lavinia Spain, John Park, Henry T. Quach, Lalit Pallan, Jennifer McQuade, Sophie Feng, Shahneen Sandhu, Victoria Atkinson, Katy Tsai, Georgina V. Long, James Larkin, Zeynep Eroglu, Douglas B. Johnson, Ryan Sullivan, Geoffrey K. Herkes, Andrew Henderson, Matteo S. Carlino
Publikováno v:
Melanoma Research. 32:451-459
Anti-programmed cell death protein 1 (PD1) antibodies, pembrolizumab and nivolumab, alone or in combination with ipilimumab, have become standard treatment for melanoma and multiple other malignancies. Neurological adverse effects are rare and have n
Autor:
Xue Bai, Alexander N. Shoushtari, Allison Betof Warner, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lalit Pallan, Catriona Harvey, Michelle S. Kim, Gyulnara Kasumova, Tatyana Sharova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Dennie T. Frederick, Keith T. Flaherty, Georgina V. Long, Alexander M. Menzies, Ryan J. Sullivan, Genevieve M. Boland, Douglas B. Johnson, Jun Guo
Publikováno v:
British Journal of Dermatology. 187:401-410
Background Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as Eas
Autor:
Emily J Anstadt, Brian Chu, Nikhil Yegya-Raman, Xiaoyan Han, Abigail Doucette, Kendra Poirier, Jahan J Mohiuddin, Amit Maity, Andrea Facciabene, Ravi K Amaravadi, Giorgos C Karakousis, Justine V Cohen, Tara C Mitchell, Lynn M Schuchter, John N Lukens
Publikováno v:
The Oncologist. 27:799-808
Background For patients with melanoma, gastrointestinal immune-related adverse events are common after receipt of anti-CTLA4 therapy. These present difficult decision points regarding whether to discontinue therapy. Detailing the situations in which
Autor:
Richard G. Abramson, Zeynep Eroglu, Ryan J. Sullivan, Florian J. Fintelmann, Kenneth L. Gage, Amber L. Voorhees, Brian D. Schlick, Daniel Y. Wang, Alexandra M. Haugh, Noura Ayoubi, Justine V. Cohen, Kevin B. Taylor, Douglas B. Johnson
Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti–PD-1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c888df97c4a2e89ceb27a0b0ee4c655
https://doi.org/10.1158/2326-6066.c.6549933.v1
https://doi.org/10.1158/2326-6066.c.6549933.v1
Autor:
Antoni Ribas, John M. Kirkwood, Larissa A. Korde, Elad Sharon, Nageatte Ibrahim, Sama Ahsan, Scot W. Ebbinghaus, Krishna S. Gunturu, Magdalena Kovacsovics-Bankowski, Brian Gastman, Zeynep Eroglu, James Moon, Hongli Li, Douglas B. Johnson, Ragini R. Kudchadkar, Bartosz Chmielowski, Robert M. Conry, Karl D. Lewis, Pauline Funchain, Kari Kendra, Elizabeth I. Buchbinder, Justine V. Cohen, Nikhil I. Khushalani, Thach-Giao Truong, Teresa M. Petrella, Michael V. Knopp, Vernon K. Sondak, Ahmad A. Tarhini, Sapna P. Patel, Megan Othus, Kenneth F. Grossmann
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70860ad8a591df39f1504fb8bc1ae75a
https://doi.org/10.1158/2159-8290.22541236.v1
https://doi.org/10.1158/2159-8290.22541236.v1